- Home
- PFLT vs GYRE Comparison
PFLT vs GYRE Comparison
Compare PFLT & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFLT
- GYRE
- Stock Information
- Founded
- PFLT 2010
- GYRE 2002
- Country
- PFLT United States
- GYRE United States
- Employees
- PFLT N/A
- GYRE N/A
- Industry
- PFLT Finance: Consumer Services
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- PFLT Finance
- GYRE Health Care
- Exchange
- PFLT Nasdaq
- GYRE Nasdaq
- Market Cap
- PFLT 1.1B
- GYRE 897.1M
- IPO Year
- PFLT N/A
- GYRE N/A
- Fundamental
- Price
- PFLT $10.19
- GYRE $8.18
- Analyst Decision
- PFLT Buy
- GYRE
- Analyst Count
- PFLT 5
- GYRE 0
- Target Price
- PFLT $10.95
- GYRE N/A
- AVG Volume (30 Days)
- PFLT 846.4K
- GYRE 77.8K
- Earning Date
- PFLT 08-11-2025
- GYRE 08-11-2025
- Dividend Yield
- PFLT 12.07%
- GYRE N/A
- EPS Growth
- PFLT N/A
- GYRE N/A
- EPS
- PFLT 0.81
- GYRE 0.02
- Revenue
- PFLT $247,973,000.00
- GYRE $102,189,000.00
- Revenue This Year
- PFLT $45.12
- GYRE $21.04
- Revenue Next Year
- PFLT $9.18
- GYRE $89.64
- P/E Ratio
- PFLT $12.54
- GYRE $176.20
- Revenue Growth
- PFLT 48.88
- GYRE N/A
- 52 Week Low
- PFLT $8.82
- GYRE $6.11
- 52 Week High
- PFLT $11.90
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- PFLT 38.93
- GYRE 58.07
- Support Level
- PFLT $10.10
- GYRE $7.35
- Resistance Level
- PFLT $10.60
- GYRE $8.30
- Average True Range (ATR)
- PFLT 0.16
- GYRE 0.45
- MACD
- PFLT -0.03
- GYRE 0.08
- Stochastic Oscillator
- PFLT 18.63
- GYRE 92.86
About PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.